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eratoacanthomas (KAs) and squamous cell
carcinomas (SCCs) are common epidermal
neoplasms, particularly in sun-exposed
areas of fair-skinned individuals. Although surgical
excision is the standard of care, eruptive KAs and
SCCs provide a therapeutic challenge. We present an
unusual case of a patient who developed eruptive
low-grade keratoacanthomatous atypical squamous
proliferations (KASPs) in split-thickness skin graft
(STSG) donor and recipient sites after SCC excision.CASE REPORT
A 73-year-old Caucasian woman with a history of
basal cell carcinoma, SCC, and no known chemical
or occupational exposures presented in November
2013 with multiple large well-differentiated SCCs of
the bilateral lower extremities. She underwent wide
local excision of 3 SCCs on the right leg and 1 SCC of
the left leg. All excision sites were repaired with a
STSG from a donor site on the proximal aspect of her
right thigh.
One month after surgery, the graft donor site on
the proximal aspect of her right thigh and the SCC
excision site on the right shin that had been repaired
with the STSG developed numerous erythematous
firm papules (Figs 1 and 2). Histopathology of 2
papules biopsied on the STSG donor site on the
proximal aspect of her right thigh showed epidermal
hyperkeratosis and infiltration into the papillary
dermis by irregular strands of large cells withthe Department of Dermatology, Feinberg School of Med-
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nuclei, consistent with low-grade KASPs (Fig 3). A
biopsy specimen of a papule on the SCC excision site
on the front of her right shin that had been repaired
by the graft showed similar pathology. Therapy with
acitretin (25 mg) by mouth daily was initiated and the
KASPs on the right thigh STSG donor site promptly
resolved. Acitretin therapy was complicated by a
significant transaminitis and subsequently discontin-
ued without recurrence of these neoplasms on the
right thigh. The patient required repeated wide local
excision of the right shin for multiple KASPs that were
persistent despite acitretin therapy and the defect was
repaired with a STSG from a donor site on the
proximal aspect of her left thigh.
After surgery, the left thigh graft donor site
developed multiple firm papules similar to those
that had developed in the right thigh donor site. A
biopsy specimen of 2 papules on the left thigh graft
donor site showed keratin-filled plugs with epithelial
collarettes and large and glassy-appearing keratino-
cytes without significant atypia, consistent with KAs
(Fig 4). Therapy with oral acitretin was restarted withUniversity, 676 N St Clair St, Suite 1600, Chicago, IL 60611.
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Fig 3. Right thigh, keratoacanthomatous atypical squa-
mous proliferation. (Hematoxylin-eosin stain; original
magnification: 310.)
Fig 4. Left thigh, keratoacanthomatous atypical squamous
proliferation. (Hematoxylin-eosin stain; original magnifi-
cation: 310.)
Fig 1. Right thigh split-thickness skin graft donor site.
Fig 2. Right shin split-thickness skin graft recipient site.
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her left thigh. Because of a recurrent transaminitis
that was persistent even on a lower dose of acitretin
(10 mg) by mouth daily, acitretin was discontinued.
The STSG donor sites on the bilateral thighs
remained clear of KASPs and KAs, however the
patient again went on to develop recurrent low-
grade KASPs on the front of her right shin. She was
treated with a combination of cryosurgery and
topical 5-fluorouracil under occlusion with partial
involution of these neoplasms. Radiation therapy isplanned for future recurrences not responsive to
topical treatments and cryotherapy.
DISCUSSION
KAs and KASPs are rapidly proliferating
epidermal tumors that are considered a variant of
SCC and thought to be follicular in origin. These
neoplasms most commonly occur on sun-exposed
areas of light-skinned middle-aged and older in-
dividuals as single lesions. Multiple KAs have been
described in the Ferguson-Smith, Grzybowski, and
Witten and Zak subtypes and in genetic syndromes
with defects in DNA repair systems such as Muir-
Torre and xeroderma pigmentosum. The pathogen-
esis of KAs and SCCs is not fully understood but these
entities have been associated with chemical carcin-
ogen exposure, immunosuppression, human papil-
lomavirus, and trauma.
The presentation of multiple eruptive KASPs
occurring within a surgical site and STSG donor site
is rare. Few case reports describe a similar presen-
tation to our patient in which multiple KAs or SCCs
developed at a surgical wound after SCC excision.1,2
Approximately 10 cases of a single KA or well-
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have been reported since this entity was first
described over 60 years ago. However, only 1 case
of numerous KAs occurring in a STSG donor and
recipient site was identified.3 Eruptive KAs within
sites of diffuse trauma caused by fractional photo-
thermolysis, medium-depth chemical peels, tattoos,
and photodynamic therapy with microdermabrasion
have been reported suggesting a role of pathergy
triggering these neoplasms.4-8 Pathergy has also
been described as a precipitant of KAs in the
Grzybowski subtype. It is unclear to what degree
pathergy may have triggered atypical squamous
proliferation development in our patient or if trauma
may have caused chronic inflammation that pro-
moted the growth of these neoplasms within vulner-
able sites in an already predisposed individual. On
review of our patient’s pathology from her initial
excisions and subsequent biopsy specimens of
eruptive neoplasms postoperatively, all appeared
histologically similar andwithin the spectrum of low-
grade KASPs. These atypical squamous prolifera-
tions (which may otherwise be identified as either
well-differentiated SCCs or KAs) are all believed to
be part of the same entity in this patient. In an
otherwise healthy individual who has continued to
do well clinically, it is unclear to what degree these
are truly neoplastic with metastatic potential or if
they are a manifestation of chronic inflammation.
The clinical presentation of eruptive KASPs pre-
sents a therapeutic challenge. Surgical options
include excision, Mohs micrographic surgery, and
cryosurgery. When lesions are multiple, large, or
surgery is contraindicated, treatment with an oral
retinoidmay be successful, however systemic toxicity
may limit the use of these agents as was the case in
our patient. Topical and intralesional therapies thathave anecdotally been reported as beneficial include
topical 5-fluorouracil, intralesional 5-fluorouracil,
intralesional methotrexate, intralesional bleomycin,
intralesional interferon alfa-2b, and intralesional
corticosteroids.9,10 Radiation therapy may also be
considered to control localized disease.REFERENCES
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